Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared on LinkedIn:
”As I close the chapter on ASH2025, I’m energized by the conversations happening across the hematology community.
Being on the ground at conferences like ASH is so important for our work in rare blood disorders.
It’s where we connect with the researchers advancing the science, the clinicians treating patients every day, and the advocates representing the communities we serve – a convergence of those who have a real stake in the research, the data, and the outcomes.
The breadth of scientific innovation presented this year was impressive.
I heard a lot about the potential of multi-immune modulation as an approach to rare autoimmune conditions like Immune Thrombocytopenia (ITP), warm Autoimmune Hemolytic Anemia (wAIHA), and Sickle Cell Disease (SCD).
While hemophilia remains core to our mission, I’ve enjoyed expanding our scientific discussions with healthcare providers who manage patients with Complex Immune Dysregulation (CID) conditions.
There’s clearly significant room for improvement for these patients who often have no treatments approved specifically for their condition.
These face-to-face conversations remind us why we do what we do.
A red thread throughout all my discussions was how our work translates to real impact in patients’ daily lives.
Hearing directly from the hematology community about the challenges they face, the progress being made, and the work still ahead helps inform our path forward.
What were some of your key learnings from the meeting?”
Stay updated with Hemostasis Today.
-
Dec 11, 2025, 16:18Caitlin Raymond’s Commentary on Artificial Intelligence in Transfusion Medicine is Out!
-
Dec 11, 2025, 15:20Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
-
Dec 11, 2025, 15:05Kristof Vercruysse on ”First in Human” Presented at ASH25
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report